Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.
|Original language||English (US)|
|Number of pages||6|
|Journal||European Oncology and Haematology|
|State||Published - Jan 1 2018|
- Advanced disease
- Hepatocellular carcinoma
ASJC Scopus subject areas